Key Developments: SQI Diagnostics Inc (SQD.V)

SQD.V on TSX Venture Exchange

28 Jan 2015
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Latest Key Developments (Source: Significant Developments)

SQI Diagnostics announces debt financing of up to $4 mln
Wednesday, 21 Jan 2015 04:53pm EST 

SQI Diagnostics Inc:Intends to complete a non-brokered private placement of secured debentures of up to $4 million.Debentures will bear interest at a rate of 10pct per annum on the principal amount outstanding and will be repayable 60 months from the date issued.Debentures will be secured by a general security agreement over all the present and future assets of the Company including intangibles.Says consideration for the Debentures, the company is issuing an aggregate of up on four million common share purchase warrants.Each Warrant will entitle the holder to purchase one common share of the Corporation at a price of $0.60 and is exercisable at any time up to 60 months after the date of issue.Intends to use the net proceeds to fund the Company's product development and commercialization programs, sales and marketing and for general working capital purposes.Expects an initial closing of the Offering on or about Jan. 23, with additional closings in Feb.  Full Article

SQI Diagnostics Inc gets additional business from UK-based customer
Monday, 15 Dec 2014 10:32am EST 

SQI Diagnostics Inc:Has advanced its existing commercial relationship with a UK-based customer, enabling the company to manufacture a 19-plex infectious disease.  Full Article

SQI Diagnostics receives FDA clearance for Ig_plex Celiac DGP Panel for Sale in the United States
Friday, 7 Nov 2014 03:50pm EST 

SQI Diagnostics Inc:Announced that it has received notice that the United States Food and Drug Administration (FDA) has cleared the company to market its Celiac Panel in the United States (US).In addition to its suite of FDA cleared assays for celiac disease and rheumatoid arthritis, SQI is building a pipeline of other IVD autoimmune assays, including a quantitative 12-plex panel for lupus, a quantitative 3-plex panel for vasculitis, and an 8-plex panel for Crohn's disease.  Full Article

SQI Diagnostics announces new Chairman of board of directors
Monday, 29 Sep 2014 09:05am EDT 

SQI Diagnostics Inc:Appoints Peter Winkley to Chairman of Board of Directors of SQI, replacing Claude Ricks.Says Ricks will continue to serve as Director on Board and will continue to provide leadership to company.  Full Article

SQI Diagnostics to begin Trading on OTCQX Marketplace in the United States
Wednesday, 17 Sep 2014 09:05am EDT 

SQI Diagnostics Inc:Announced that its common shares have been approved for trading in the United States on the OTCQX marketplace.Trading is expected to commence on Sept. 17 on the OTCQX under the symbol SQIDF.  Full Article

SQI Diagnostics contracted to Automate Pathogen Detection Assays
Friday, 22 Aug 2014 08:30am EDT 

SQI Diagnostics Inc:Enters into Master Service Agreement to contract with UK-based company to automate their DNA-based pathogen detection assays.During initial phase of this agreement, SQI will be paid to deliver an automated working prototype of one of customer's assays, operational on SQI's sqid lite(tm) system.Initial phase is scheduled for completion by mid-Sept 2014.It is anticipated that other molecular diagnostic tests will be commissioned in separate agreement following successful implementation of initial phase.First assay being automated is used to identify pathogens in raw milk from dairy cows.Currently, dairy cows are routinely tested for health through global network of laboratories and when symptoms of bacterial infections appear, pathogens are commonly detected using traditional plate cultures.New application can be used for much faster and more accurate identification of multiple pathogens simultaneously.The UK-based company is developing additional assays for agriculture, food safety and human pathogen testing, intended to screen high volumes of samples on a regular basis.  Full Article

SQI Diagnostics Inc hired by global pharmaceutical company to develop two prototype multiplex immunoassays for evaluation
Tuesday, 20 May 2014 09:05am EDT 

SQI Diagnostics Inc:Says it is being paid by one of the pharmaceutical companies to develop and validate two custom multiplex anti-drug-antibody (ADA) assays.This new customer will evaluate these two products using an established drug from its portfolio in order to assess the capabilities and performance of SQI's technologies.  Full Article

SQI Diagnostics Inc completes C$4.2 mln equity financing
Thursday, 10 Apr 2014 10:35am EDT 

SQI Diagnostics Inc:Closes public offering of 8,400,000 units at price of C$0.50 per Unit for gross proceeds of C$4.2 mln.Each Unit is comprised of one common share and one Common Share purchase warrant.Each Warrant is exercisable at price of C$0.65 and entitles the holder thereof to acquire one common share until April 10, 2016.Intends to use net proceeds to fund product development and commercialization programs, sales and marketing and for general working capital purposes.  Full Article

SQI Diagnostics Inc files final prospectus for equity financing
Friday, 4 Apr 2014 11:09am EDT 

SQI Diagnostics Inc:Issue minimum of 8,000,000 units at a price of C$0.50 per unit.Gross proceeds will be C$4.0 mln.Use of net proceeds to fund product development and commercialization programs, sales and marketing and for general working capital purposes.Closing is expected on or about April 10.  Full Article

SQI Diagnostics Inc signs commercial agreement with Global Pharma Customer
Thursday, 20 Mar 2014 03:27pm EDT 

SQI Diagnostics Inc:Expands product development relationship with a global pharmaceutical company.To develop a custom multiplex test to support the pharmaceutical company's clinical drug development activities, through the entering into of a revenue-generating agreement with Global Pharma 1 to develop a 21-plex protein microarray.  Full Article

Search Stocks